The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis

Abstract Background During the COVID-19 pandemic, some populations, including immunocompromised patients, could not tolerate COVID-19 vaccination or had low responses. Evusheld is a combined neutralizing monoclonal antibody containing tixagevimab and cilgavimab. The World Health Organization (WHO) h...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Shaymaa Glhoom, Aya Fergany, Dina El-Araby, Asmaa A. Abdelkhalek, Asmaa Gomaa, Eman O. Zayed, Mohamed Abd-ElGwad
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-01-01
סדרה:	European Journal of Medical Research
נושאים:	Cilgavimab Tixagevimab Evusheld AZD7442 COVID-19
גישה מקוונת:	https://doi.org/10.1186/s40001-023-01549-x
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!